Acetadote is a drug used to minimize liver damage from acetaminophen overdoses in hospital emergency rooms.
The new patent that covers the use of 200mg/ml Acetadote formulation provides additional protection through 2025.
Cumberland chief executive officer A.J. Kazimi said the new Acetadote patent signifies an important development in the company’s effort to protect its intellectual property.
"Intellectual property protection is a key objective for the company and we will continue to seek opportunities to expand our patent portfolio," Kazimi added.
Cumberland stopped the production of the original formulation that received patent nod in April 2011, subsequent to the approval of the revised formulation.